Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500240 · ClinicalTrials.gov registry record · Phase 3
Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
NCT00500240: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00500240 is a Phase 3 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00500240, a Phase 3 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if intense management and control of blood sugar levels during treatment for acute lymphocytic leukemia, Burkitts lymphoma, or lymphoblastic lymphoma will result in decreased risk of relapse, fewer complications, and/or longer survival.
Interventions
- DRUG Insulin Glargine
- DRUG Insulin Aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2004-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500240
The ClinicalTrials.gov registry entry for NCT00500240 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Glargine is the first listed.
NCT00500240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00500240 about?
NCT00500240 is a clinical study titled "Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)". The goal of this clinical research study is to learn if intense management and control of blood sugar levels during treatment for acute lymphocytic leukemia, Burkitts lymphoma, or lymphoblastic lymphoma will result in decreased risk of relapse, fewer complications, and/or longer survival.
What is the current status of trial NCT00500240?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2004-04. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00500240?
The interventions under investigation include: Insulin Glargine (DRUG), Insulin Aspart (DRUG).
Who is sponsoring clinical trial NCT00500240?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.